CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
27 sept. 2023 07h00 HE
|
CytoSorbents
CytoSorbents summarizes real-world data from STAR Registry analysis being presented next week at European Association of Cardio-Thoracic Surgery Congress
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
19 sept. 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat...
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
11 sept. 2023 11h32 HE
|
CytoSorbents
PRINCETON, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
01 sept. 2023 16h43 HE
|
CytoSorbents
PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
31 août 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., Aug. 31, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat...
CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
01 août 2023 16h15 HE
|
CytoSorbents
Q2 2023 Total Revenue was $9.4 million, an 11% increase from $8.5 million in Q2 2022. Product sales rose 10% to $8.1 million vs $7.3 million in Q2 2022. Product gross margins grew 700 basis points...
CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
26 juil. 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer
19 juil. 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., July 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease
11 juil. 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
07 juil. 2023 07h07 HE
|
CytoSorbents
PRINCETON, N.J., July 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...